HRP20110180T1 - Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet - Google Patents
Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet Download PDFInfo
- Publication number
- HRP20110180T1 HRP20110180T1 HR20110180T HRP20110180T HRP20110180T1 HR P20110180 T1 HRP20110180 T1 HR P20110180T1 HR 20110180 T HR20110180 T HR 20110180T HR P20110180 T HRP20110180 T HR P20110180T HR P20110180 T1 HRP20110180 T1 HR P20110180T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- trifluoromethyl
- biphenyl
- phenyl
- difluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 55
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 41
- 239000012453 solvate Substances 0.000 claims abstract 41
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims abstract 2
- -1 -OR4 Chemical group 0.000 claims 83
- 125000001072 heteroaryl group Chemical group 0.000 claims 77
- 125000000623 heterocyclic group Chemical group 0.000 claims 63
- 125000003107 substituted aryl group Chemical group 0.000 claims 57
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 49
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 49
- 125000003710 aryl alkyl group Chemical group 0.000 claims 47
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 47
- 125000000547 substituted alkyl group Chemical group 0.000 claims 47
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 47
- 125000005843 halogen group Chemical group 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 238000000034 method Methods 0.000 claims 24
- 125000001188 haloalkyl group Chemical group 0.000 claims 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 19
- 125000004076 pyridyl group Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 12
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 12
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000001425 triazolyl group Chemical group 0.000 claims 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- LOKPCLOCVRXPGR-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3C=CC=CC3=CC=2C(F)(F)F)=C1F LOKPCLOCVRXPGR-UHFFFAOYSA-N 0.000 claims 6
- HDLANTLODKXVBM-UHFFFAOYSA-N 2,3-difluoro-n-[4-[3-thiophen-3-yl-5-(trifluoromethyl)-1,2,4-triazol-4-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C(=NN=C2C2=CSC=C2)C(F)(F)F)=C1F HDLANTLODKXVBM-UHFFFAOYSA-N 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- PPSKETUMTSIHFN-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 PPSKETUMTSIHFN-UHFFFAOYSA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- RODKSPSXJYTKKC-UHFFFAOYSA-N 2,3-difluoro-n-[2-fluoro-4-[2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C(=CC(=CC=2)C=2C(=CC=CC=2)C(F)(F)F)F)=C1F RODKSPSXJYTKKC-UHFFFAOYSA-N 0.000 claims 3
- DSSKDARDNCTZCD-UHFFFAOYSA-N 2,3-difluoro-n-[3-(trifluoromethyl)-4-[2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=C(C(C=3C(=CC=CC=3)C(F)(F)F)=CC=2)C(F)(F)F)=C1F DSSKDARDNCTZCD-UHFFFAOYSA-N 0.000 claims 3
- UFZWBTOIQRFNLK-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2,4,5-trimethylphenyl)phenyl]benzamide Chemical compound C1=C(C)C(C)=CC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F UFZWBTOIQRFNLK-UHFFFAOYSA-N 0.000 claims 3
- XUXCFDUQWUWQLT-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-methoxy-5-methylphenyl)phenyl]benzamide Chemical compound COC1=CC=C(C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F XUXCFDUQWUWQLT-UHFFFAOYSA-N 0.000 claims 3
- JMICNCFBFBRLIM-UHFFFAOYSA-N 2,3-difluoro-n-[4-(3-methylpent-2-en-2-yl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C(F)(F)F)C(C(C)=C(C)CC)=CC=C1NC(=O)C1=CC=CC(F)=C1F JMICNCFBFBRLIM-UHFFFAOYSA-N 0.000 claims 3
- SASKHUPJTPGMEA-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-fluoro-5-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)F)=C1F SASKHUPJTPGMEA-UHFFFAOYSA-N 0.000 claims 3
- HIRKWQUXRHXOJN-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-fluoro-6-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=CC=2F)C(F)(F)F)=C1F HIRKWQUXRHXOJN-UHFFFAOYSA-N 0.000 claims 3
- ZADZAOOGRKKHHX-UHFFFAOYSA-N 2,3-difluoro-n-[4-[3-(trifluoromethyl)-2h-indolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C2(N3C=CC=CC3=CC2)C(F)(F)F)=C1F ZADZAOOGRKKHHX-UHFFFAOYSA-N 0.000 claims 3
- QFGFRYFWZRGBQP-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-fluoro-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3C(F)=CC=CC3=CC=2C(F)(F)F)=C1F QFGFRYFWZRGBQP-UHFFFAOYSA-N 0.000 claims 3
- XPIUSJJYZREVOB-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C(OC)=CC=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F XPIUSJJYZREVOB-UHFFFAOYSA-N 0.000 claims 3
- VTXPBIAPUCMYJG-UHFFFAOYSA-N 2,3-difluoro-n-[4-[6-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C=C(OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F VTXPBIAPUCMYJG-UHFFFAOYSA-N 0.000 claims 3
- GTVMZYFJPSTISK-UHFFFAOYSA-N 2,3-difluoro-n-[4-[7-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F GTVMZYFJPSTISK-UHFFFAOYSA-N 0.000 claims 3
- RYDKPHTXHUEPFH-UHFFFAOYSA-N 2,3-difluoro-n-[4-[8-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C(OC)=CC=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F RYDKPHTXHUEPFH-UHFFFAOYSA-N 0.000 claims 3
- SFQODEMMYULEMB-UHFFFAOYSA-N 2,4,5-trifluoro-n-[4-[5-fluoro-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound C1=C(F)C(F)=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(F)=CC=CC3=CC=2C(F)(F)F)C=C1 SFQODEMMYULEMB-UHFFFAOYSA-N 0.000 claims 3
- VVOYIUOZAQJEGS-UHFFFAOYSA-N 2,4,5-trifluoro-n-[4-[5-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C(OC)=CC=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F VVOYIUOZAQJEGS-UHFFFAOYSA-N 0.000 claims 3
- GQBTWFVTPFDAHC-UHFFFAOYSA-N 2,4,5-trifluoro-n-[4-[6-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C=C(OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F GQBTWFVTPFDAHC-UHFFFAOYSA-N 0.000 claims 3
- KFDQLUJBDVXHMN-UHFFFAOYSA-N 2,4,5-trifluoro-n-[4-[7-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F KFDQLUJBDVXHMN-UHFFFAOYSA-N 0.000 claims 3
- AUYKGRUXPRZGSH-UHFFFAOYSA-N 2,4,5-trifluoro-n-[4-[8-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C(OC)=CC=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F AUYKGRUXPRZGSH-UHFFFAOYSA-N 0.000 claims 3
- JXGLLQGTDQCTAM-UHFFFAOYSA-N 2,4-dimethyl-n-[4-[2-(trifluoromethyl)phenyl]phenyl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C)=NC(C)=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1 JXGLLQGTDQCTAM-UHFFFAOYSA-N 0.000 claims 3
- NQZYZEAOLHZYPW-UHFFFAOYSA-N 2,5-difluoro-n-[4-[2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=CC(=CC=2)C=2N3C=CC=CC3=CC=2C(F)(F)F)=C1 NQZYZEAOLHZYPW-UHFFFAOYSA-N 0.000 claims 3
- NAQVBBRZJGIBOH-UHFFFAOYSA-N 2,5-difluoro-n-[4-[2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1 NAQVBBRZJGIBOH-UHFFFAOYSA-N 0.000 claims 3
- KNDPPJIUFYWIID-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-fluoro-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(F)=CC=CC3=CC=2C(F)(F)F)C=C1 KNDPPJIUFYWIID-UHFFFAOYSA-N 0.000 claims 3
- DDWIPMZMXBTQFU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C(OC)=CC=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DDWIPMZMXBTQFU-UHFFFAOYSA-N 0.000 claims 3
- RRZSDNHRDXRCFB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-methyl-2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C(F)(F)F)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 RRZSDNHRDXRCFB-UHFFFAOYSA-N 0.000 claims 3
- RTRWBBMWIXDXHU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[6-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound N12C=C(OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RTRWBBMWIXDXHU-UHFFFAOYSA-N 0.000 claims 3
- DBYQXPHQVVSMFB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[7-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DBYQXPHQVVSMFB-UHFFFAOYSA-N 0.000 claims 3
- YAGRGSPLLIWGFE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[8-methoxy-2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound FC(F)(F)C=1C=C2C(OC)=CC=CN2C=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F YAGRGSPLLIWGFE-UHFFFAOYSA-N 0.000 claims 3
- AZZPUQMQPKRIJL-UHFFFAOYSA-N 2-ethyl-5-methyl-n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyrazole-3-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1 AZZPUQMQPKRIJL-UHFFFAOYSA-N 0.000 claims 3
- PAXANZFKHKNUKR-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)-n-[4-[2-(trifluoromethyl)phenyl]phenyl]-1,3-oxazole-4-carboxamide Chemical compound O1C(C)=NC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1C(F)(F)F PAXANZFKHKNUKR-UHFFFAOYSA-N 0.000 claims 3
- SWYLSLZPJMBYGI-UHFFFAOYSA-N 3,4-dimethoxy-n-[4-[2-(trifluoromethyl)indolizin-3-yl]phenyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=CC=C(C=2N3C=CC=CC3=CC=2C(F)(F)F)C=C1 SWYLSLZPJMBYGI-UHFFFAOYSA-N 0.000 claims 3
- OMERAJJHKZZZEW-UHFFFAOYSA-N 3-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-1,1-diethylurea Chemical compound C1=CC(NC(=O)N(CC)CC)=CC=C1C1=CC(C(F)(F)F)=CC=C1C(F)(F)F OMERAJJHKZZZEW-UHFFFAOYSA-N 0.000 claims 3
- BLUOMGLQBVUWTH-UHFFFAOYSA-N 3-fluoro-n-[4-(2-methylphenyl)phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F BLUOMGLQBVUWTH-UHFFFAOYSA-N 0.000 claims 3
- WVKINTDHLSSGLX-UHFFFAOYSA-N 3-fluoro-n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1 WVKINTDHLSSGLX-UHFFFAOYSA-N 0.000 claims 3
- FDFQGFZSSOZOPH-UHFFFAOYSA-N 3-fluoro-n-[4-[3-(trifluoromethyl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)C=C1 FDFQGFZSSOZOPH-UHFFFAOYSA-N 0.000 claims 3
- OBOQPEBXELZASA-UHFFFAOYSA-N 3-methyl-n-[4-(2-methylsulfanylphenyl)phenyl]pyridine-4-carboxamide Chemical compound CSC1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C OBOQPEBXELZASA-UHFFFAOYSA-N 0.000 claims 3
- BBYVGUCKNFNBHG-UHFFFAOYSA-N 3-methyl-n-[4-(2-propan-2-ylphenyl)phenyl]pyridine-4-carboxamide Chemical compound CC(C)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C BBYVGUCKNFNBHG-UHFFFAOYSA-N 0.000 claims 3
- OSMAGAVKVRGYGR-UHFFFAOYSA-N 3-methylpyridine-4-carboxylic acid Chemical compound CC1=CN=CC=C1C(O)=O OSMAGAVKVRGYGR-UHFFFAOYSA-N 0.000 claims 3
- VRYAOEYBOOCTDR-UHFFFAOYSA-N 4-(trifluoromethyl)-n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=NC=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1 VRYAOEYBOOCTDR-UHFFFAOYSA-N 0.000 claims 3
- GXNXKZCFHUUEFU-UHFFFAOYSA-N 4-fluoro-n-[4-[2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1 GXNXKZCFHUUEFU-UHFFFAOYSA-N 0.000 claims 3
- SVBUQWXXBPEXNY-UHFFFAOYSA-N 4-methyl-n-[4-(2-methylindolizin-3-yl)phenyl]thiadiazole-5-carboxamide Chemical compound CC=1C=C2C=CC=CN2C=1C(C=C1)=CC=C1NC(=O)C=1SN=NC=1C SVBUQWXXBPEXNY-UHFFFAOYSA-N 0.000 claims 3
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 108090000862 Ion Channels Proteins 0.000 claims 3
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- DIIFIXDKOOPCAR-UHFFFAOYSA-N methyl 3-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F DIIFIXDKOOPCAR-UHFFFAOYSA-N 0.000 claims 3
- AYJXHVVXQGQMAD-UHFFFAOYSA-N methyl 3-[4-[(2,3-difluorobenzoyl)amino]phenyl]-5-methoxy-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(OC)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F AYJXHVVXQGQMAD-UHFFFAOYSA-N 0.000 claims 3
- ZHCZWORURPKSCB-UHFFFAOYSA-N methyl 3-[4-[(2,4,5-trifluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F ZHCZWORURPKSCB-UHFFFAOYSA-N 0.000 claims 3
- UQZZNFPVJIJKIT-UHFFFAOYSA-N methyl 3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F UQZZNFPVJIJKIT-UHFFFAOYSA-N 0.000 claims 3
- IJXIARDLYSGWSL-UHFFFAOYSA-N methyl 3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-methoxy-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(OC)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F IJXIARDLYSGWSL-UHFFFAOYSA-N 0.000 claims 3
- VLZKOGFREJDPGT-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(Cl)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F VLZKOGFREJDPGT-UHFFFAOYSA-N 0.000 claims 3
- VMCAIVHSLYANJU-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-7-carboxylate Chemical compound FC(F)(F)C=1C=C2C=C(C(=O)OC)C=C(Cl)N2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F VMCAIVHSLYANJU-UHFFFAOYSA-N 0.000 claims 3
- CZOWQOJYJWMBGP-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,4,5-trifluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(Cl)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F CZOWQOJYJWMBGP-UHFFFAOYSA-N 0.000 claims 3
- VICUSRNZVKWVEZ-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,4,5-trifluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-7-carboxylate Chemical compound FC(F)(F)C=1C=C2C=C(C(=O)OC)C=C(Cl)N2C=1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F VICUSRNZVKWVEZ-UHFFFAOYSA-N 0.000 claims 3
- JWQUQOHUTYGXTC-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(Cl)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F JWQUQOHUTYGXTC-UHFFFAOYSA-N 0.000 claims 3
- UCGATTXUVRZMDQ-UHFFFAOYSA-N methyl 5-chloro-3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-7-carboxylate Chemical compound FC(F)(F)C=1C=C2C=C(C(=O)OC)C=C(Cl)N2C=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F UCGATTXUVRZMDQ-UHFFFAOYSA-N 0.000 claims 3
- MILUUJCYYCFTDC-UHFFFAOYSA-N methyl 5-methoxy-3-[4-[(2,4,5-trifluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)indolizine-6-carboxylate Chemical compound N12C(OC)=C(C(=O)OC)C=CC2=CC(C(F)(F)F)=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F MILUUJCYYCFTDC-UHFFFAOYSA-N 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- AWSLHGOLWFEELK-UHFFFAOYSA-N n-[4-(2,5-dichlorophenyl)phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(Cl)C=2)Cl)=C1F AWSLHGOLWFEELK-UHFFFAOYSA-N 0.000 claims 3
- JDRVPORPMVPGLD-UHFFFAOYSA-N n-[4-(2,5-dichlorophenyl)phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(Cl)C=2)Cl)C=C1 JDRVPORPMVPGLD-UHFFFAOYSA-N 0.000 claims 3
- AIWPFUYDXBUFGY-UHFFFAOYSA-N n-[4-(2,5-diethylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound CCC1=CC=C(CC)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 AIWPFUYDXBUFGY-UHFFFAOYSA-N 0.000 claims 3
- FCEZDQJVOFOLSE-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-2,3-difluorobenzamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C=3C(=C(F)C=CC=3)F)=CC=2)=C1 FCEZDQJVOFOLSE-UHFFFAOYSA-N 0.000 claims 3
- SYCDGKRZAAXWDM-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-2,6-difluorobenzamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 SYCDGKRZAAXWDM-UHFFFAOYSA-N 0.000 claims 3
- QFRHSVYOONQQDG-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-2-methylbenzamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3)C)=CC=2)=C1 QFRHSVYOONQQDG-UHFFFAOYSA-N 0.000 claims 3
- GFEIWXNLDKUWIK-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-3-fluoropyridine-4-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)=C1 GFEIWXNLDKUWIK-UHFFFAOYSA-N 0.000 claims 3
- WJFCPKXXHNSABN-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 WJFCPKXXHNSABN-UHFFFAOYSA-N 0.000 claims 3
- LYQZSCWNQRGLGX-UHFFFAOYSA-N n-[4-(2,5-dimethoxyphenyl)phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C=CC(NC(=O)C3=C(N=NS3)C)=CC=2)=C1 LYQZSCWNQRGLGX-UHFFFAOYSA-N 0.000 claims 3
- QARVELYUQXUXPD-UHFFFAOYSA-N n-[4-(2,5-dimethylphenyl)phenyl]-2,3-difluorobenzamide Chemical compound CC1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=C(F)C=CC=3)F)=CC=2)=C1 QARVELYUQXUXPD-UHFFFAOYSA-N 0.000 claims 3
- XMOXGTRKFABWCI-UHFFFAOYSA-N n-[4-(2,5-dimethylphenyl)phenyl]-2,6-difluorobenzamide Chemical compound CC1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 XMOXGTRKFABWCI-UHFFFAOYSA-N 0.000 claims 3
- LTOLCFSKQADMSS-UHFFFAOYSA-N n-[4-(2,5-dimethylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 LTOLCFSKQADMSS-UHFFFAOYSA-N 0.000 claims 3
- KHFIUDNMDXTWNI-UHFFFAOYSA-N n-[4-(2-ethylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound CCC1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C KHFIUDNMDXTWNI-UHFFFAOYSA-N 0.000 claims 3
- QATQHJQOLQPIRZ-UHFFFAOYSA-N n-[4-(2-methoxy-5-methylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C QATQHJQOLQPIRZ-UHFFFAOYSA-N 0.000 claims 3
- AWWXCSDSZCUWJM-UHFFFAOYSA-N n-[4-(5-acetyl-2-methoxyphenyl)phenyl]-2,3-difluorobenzamide Chemical compound COC1=CC=C(C(C)=O)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F AWWXCSDSZCUWJM-UHFFFAOYSA-N 0.000 claims 3
- CMRMTMIMVCKYRY-UHFFFAOYSA-N n-[4-(5-acetyl-2-methoxyphenyl)phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound COC1=CC=C(C(C)=O)C=C1C(C=C1)=CC=C1NC(=O)C1=C(C)N=NS1 CMRMTMIMVCKYRY-UHFFFAOYSA-N 0.000 claims 3
- IPLAIQHWYPFYGK-UHFFFAOYSA-N n-[4-(5-chloro-2-ethoxyphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound CCOC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C IPLAIQHWYPFYGK-UHFFFAOYSA-N 0.000 claims 3
- VFPMSRIISKWJAQ-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)phenyl]-2,3-difluorobenzamide Chemical compound COC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F VFPMSRIISKWJAQ-UHFFFAOYSA-N 0.000 claims 3
- OBUCADJIHSQDOH-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)phenyl]-2,4,5-trifluorobenzamide Chemical compound COC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C=C1F OBUCADJIHSQDOH-UHFFFAOYSA-N 0.000 claims 3
- YMWMWBUCWBLRRE-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)phenyl]-3-fluoropyridine-4-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F YMWMWBUCWBLRRE-UHFFFAOYSA-N 0.000 claims 3
- CZODDPCOZRPILV-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxyphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C CZODDPCOZRPILV-UHFFFAOYSA-N 0.000 claims 3
- XWDSDPOAPWWTRU-UHFFFAOYSA-N n-[4-(5-cyano-2-methoxyphenyl)phenyl]-2,3-difluorobenzamide Chemical compound COC1=CC=C(C#N)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F XWDSDPOAPWWTRU-UHFFFAOYSA-N 0.000 claims 3
- ZXLMCFOMRMQXLZ-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=C(C(F)(F)F)C(C=2C=CC(NC(=O)C=3ON=CC=3)=CC=2)=C1 ZXLMCFOMRMQXLZ-UHFFFAOYSA-N 0.000 claims 3
- AZIBAKRFJNYNEO-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1F AZIBAKRFJNYNEO-UHFFFAOYSA-N 0.000 claims 3
- OOYPXXUSPRQVFT-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound FC(F)(F)C1=CC=C(C(F)(F)F)C(C=2C=CC(NC(=O)C=3C=4OCCOC=4C=CC=3)=CC=2)=C1 OOYPXXUSPRQVFT-UHFFFAOYSA-N 0.000 claims 3
- STNNMCWOBNDNKA-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,3-dimethylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1C STNNMCWOBNDNKA-UHFFFAOYSA-N 0.000 claims 3
- GRZSAMOBNGCJOZ-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,5-difluorobenzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1 GRZSAMOBNGCJOZ-UHFFFAOYSA-N 0.000 claims 3
- DCCBGJMDDKTXFR-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,5-dimethylpyrazole-3-carboxamide Chemical compound CN1N=C(C)C=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 DCCBGJMDDKTXFR-UHFFFAOYSA-N 0.000 claims 3
- DIPKRDUMYXHGED-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 DIPKRDUMYXHGED-UHFFFAOYSA-N 0.000 claims 3
- ITDRLFXSUNQUCT-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 ITDRLFXSUNQUCT-UHFFFAOYSA-N 0.000 claims 3
- NWKXLNMUKDLVNL-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=NC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 NWKXLNMUKDLVNL-UHFFFAOYSA-N 0.000 claims 3
- CBXVBEVNTQIZJG-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 CBXVBEVNTQIZJG-UHFFFAOYSA-N 0.000 claims 3
- ARBSTFMOMBBEPA-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-chloro-2-methylbenzamide Chemical compound CC1=C(Cl)C=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 ARBSTFMOMBBEPA-UHFFFAOYSA-N 0.000 claims 3
- GUFNCESSHKLNFB-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-fluoro-2-methylbenzamide Chemical compound CC1=C(F)C=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 GUFNCESSHKLNFB-UHFFFAOYSA-N 0.000 claims 3
- YIGKCCOEDOTGOC-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 YIGKCCOEDOTGOC-UHFFFAOYSA-N 0.000 claims 3
- YJSSRKJNFIABEH-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-methoxy-2-methylbenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1C YJSSRKJNFIABEH-UHFFFAOYSA-N 0.000 claims 3
- PSMOZGNRGSEFCS-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-methyl-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 PSMOZGNRGSEFCS-UHFFFAOYSA-N 0.000 claims 3
- GWFQDZLHSGIQQR-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-methylimidazole-4-carboxamide Chemical compound CN1C=NC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 GWFQDZLHSGIQQR-UHFFFAOYSA-N 0.000 claims 3
- XHSDIRNUHNMNNA-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)C=C1 XHSDIRNUHNMNNA-UHFFFAOYSA-N 0.000 claims 3
- MVXUADGWVCMXHZ-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1C MVXUADGWVCMXHZ-UHFFFAOYSA-N 0.000 claims 3
- AWWJEAXMFGXWPH-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=N1 AWWJEAXMFGXWPH-UHFFFAOYSA-N 0.000 claims 3
- VKDISYKBFFETTH-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]-5-methyl-1,2-oxazole-4-carboxamide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1C VKDISYKBFFETTH-UHFFFAOYSA-N 0.000 claims 3
- NZNGKOPYISEFEG-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)phenyl]phenyl]thiadiazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=C(C(F)(F)F)C(C=2C=CC(NC(=O)C=3N=NSC=3)=CC=2)=C1 NZNGKOPYISEFEG-UHFFFAOYSA-N 0.000 claims 3
- XJWAMOYSDNAJBB-UHFFFAOYSA-N n-[4-[2-(dimethylamino)-5-(trifluoromethoxy)phenyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound CN(C)C1=CC=C(OC(F)(F)F)C=C1C(C=C1)=CC=C1NC(=O)C1=C(C)N=NS1 XJWAMOYSDNAJBB-UHFFFAOYSA-N 0.000 claims 3
- XFZIFHKGOFRWQM-UHFFFAOYSA-N n-[4-[2-(dimethylamino)-5-methoxyphenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(N(C)C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 XFZIFHKGOFRWQM-UHFFFAOYSA-N 0.000 claims 3
- RXWIVLAWCPUVIM-UHFFFAOYSA-N n-[4-[2-(dimethylcarbamoyl)phenyl]phenyl]-2,3-difluorobenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F RXWIVLAWCPUVIM-UHFFFAOYSA-N 0.000 claims 3
- IRCBDIAWUVTZQS-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyrazine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CN=CC=N1 IRCBDIAWUVTZQS-UHFFFAOYSA-N 0.000 claims 3
- ULHIUBLDSQPXNI-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=CC=N1 ULHIUBLDSQPXNI-UHFFFAOYSA-N 0.000 claims 3
- DGXGZABVIDHAGT-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 DGXGZABVIDHAGT-UHFFFAOYSA-N 0.000 claims 3
- OMVYQTCZIGVSOI-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1 OMVYQTCZIGVSOI-UHFFFAOYSA-N 0.000 claims 3
- BUFCMFZEYHEEDY-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)phenyl]phenyl]thiophene-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=CS1 BUFCMFZEYHEEDY-UHFFFAOYSA-N 0.000 claims 3
- OHHIGBIGGBDEJY-UHFFFAOYSA-N n-[4-[2-chloro-5-(trifluoromethyl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)C=C1 OHHIGBIGGBDEJY-UHFFFAOYSA-N 0.000 claims 3
- GOLKVSXQONDNNF-UHFFFAOYSA-N n-[4-[2-chloro-5-(trifluoromethyl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)C=C1 GOLKVSXQONDNNF-UHFFFAOYSA-N 0.000 claims 3
- NWYZKPUWWPUBFA-UHFFFAOYSA-N n-[4-[2-chloro-5-(trifluoromethyl)phenyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C(F)(F)F)Cl)=C1C NWYZKPUWWPUBFA-UHFFFAOYSA-N 0.000 claims 3
- BYDKKUFSIJOVFC-UHFFFAOYSA-N n-[4-[3,5-bis(trifluoromethyl)-1,2,4-triazol-4-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C(=NN=C2C(F)(F)F)C(F)(F)F)=C1F BYDKKUFSIJOVFC-UHFFFAOYSA-N 0.000 claims 3
- NBGBCUVPHXLEQI-UHFFFAOYSA-N n-[4-[3,5-bis(trifluoromethyl)-1,2,4-triazol-4-yl]phenyl]-3-methylthiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC=2C=CC(=CC=2)N2C(=NN=C2C(F)(F)F)C(F)(F)F)=C1C NBGBCUVPHXLEQI-UHFFFAOYSA-N 0.000 claims 3
- YKIPGTVZUNPXDG-UHFFFAOYSA-N n-[4-[3-cyano-5-(trifluoromethyl)pyridin-2-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC(=CN=2)C(F)(F)F)C#N)=C1F YKIPGTVZUNPXDG-UHFFFAOYSA-N 0.000 claims 3
- PPBFLKBIPGUOBK-UHFFFAOYSA-N n-[4-[5-chloro-2,7-bis(trifluoromethyl)indolizin-3-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3C(Cl)=CC(=CC3=CC=2C(F)(F)F)C(F)(F)F)=C1F PPBFLKBIPGUOBK-UHFFFAOYSA-N 0.000 claims 3
- AZAZERJRGZRUSK-UHFFFAOYSA-N n-[4-[5-chloro-2,7-bis(trifluoromethyl)indolizin-3-yl]phenyl]-2,4,5-trifluorobenzamide Chemical compound C1=C(F)C(F)=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(Cl)=CC(=CC3=CC=2C(F)(F)F)C(F)(F)F)C=C1 AZAZERJRGZRUSK-UHFFFAOYSA-N 0.000 claims 3
- CUYAHNAGPWPSQR-UHFFFAOYSA-N n-[4-[5-chloro-2,7-bis(trifluoromethyl)indolizin-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(Cl)=CC(=CC3=CC=2C(F)(F)F)C(F)(F)F)C=C1 CUYAHNAGPWPSQR-UHFFFAOYSA-N 0.000 claims 3
- CRWBENFXHYJELS-UHFFFAOYSA-N n-[4-[5-chloro-2-(difluoromethoxy)phenyl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound FC(F)OC1=CC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F CRWBENFXHYJELS-UHFFFAOYSA-N 0.000 claims 3
- FOFYPVUQLVDITE-UHFFFAOYSA-N n-[4-[5-chloro-2-(trifluoromethyl)indolizin-3-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3C(Cl)=CC=CC3=CC=2C(F)(F)F)=C1F FOFYPVUQLVDITE-UHFFFAOYSA-N 0.000 claims 3
- ZUGYEJNIINYAPS-UHFFFAOYSA-N n-[4-[5-chloro-2-(trifluoromethyl)indolizin-3-yl]phenyl]-2,4,5-trifluorobenzamide Chemical compound C1=C(F)C(F)=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(Cl)=CC=CC3=CC=2C(F)(F)F)C=C1 ZUGYEJNIINYAPS-UHFFFAOYSA-N 0.000 claims 3
- VTLUYFHQAXHRPA-UHFFFAOYSA-N n-[4-[5-chloro-2-(trifluoromethyl)indolizin-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2N3C(Cl)=CC=CC3=CC=2C(F)(F)F)C=C1 VTLUYFHQAXHRPA-UHFFFAOYSA-N 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000003618 TRPM4 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Abstract
In vitro postupak inhibicije aktivacije imunoloških stanica naznačen time da se sastoji od primjene na stanicu spoja formule (I): (I) ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu: X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil; Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi; A je -CH=CH-, -CZ=CH-, ili -CH=CZ-;svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;L je poveznik odabran iz skupine koja sadrži -NRCH2-, i -NR-C(O)-; svaki R je nezavisno odabran od -H, alkila, acetila, tert-butoksikarbonila, benziloksikarbonila; R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril; R4 i R5 za svaku pojavu su, nezavisno, H1 opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; n je 0 ili cijeli broj od 1 do 4; ip je 0, 1, ili 2. Patent sadrži još 60 patentnih zahtjeva.
Claims (61)
1. In vitro postupak inhibicije aktivacije imunoloških stanica naznačen time da se sastoji od primjene na stanicu spoja formule (I):
[image]
(I)
ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
A je -CH=CH-, -CZ=CH-, ili -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2,
-NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži -NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, tert-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu su, nezavisno, H1 opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4; i
p je 0, 1, ili 2.
2. In vitro postupak inhibicije proizvodnje citokina u stanici, naznačen time da se sastoji od primjene na stanicu spoja predstavljenog sa slijedećom strukturnom formulom:
[image]
(I)
ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkil, halogeniranog C1-C4 alkil, ili C1-C4 alkoksi;
A je -CH=CH-, -CZ=CH-, ili -CH=CZ-,
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2 , -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili-S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, tert-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4; i
p je 0, 1, ili 2.
3. Postupak prema zahtjevu 2, naznačen time da citokin koji je inhibiran je odabran iz skupine koja sadrži IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF-α, IFN-y i njihove kombinacije.
4. In vitro postupak modulacije ionskog kanala u stanici, naznačen time da je ionski kanal uključen u aktivaciju imunih stanica, a sastoji se od primjene na stanicu spoja predstavljenog sa slijedećom strukturnom formulom:
[image]
(I)
ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
A je -CH=CH-, -CZ=CH-, ili -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani je opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je cijeli broj odabran od 0-4; i
p je 0, 1, ili 2.
5. Postupak prema zahtjevu 4, naznačen time da ionski kanal je TRPM4.
6. In vitro postupak inhibicije proliferacije T-stanice i/ili B-stanice kod odgovora na antigen, naznačen time da se sastoji od davanja stanici spoja predstavljenog sa slijedećom strukturnom formulom:
[image]
(I)
ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi; je -CH=CH-, -CZ=CH-, ili -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2- i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc- butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4; i
p je 0,1, ili 2.
7. Postupak prema zahtjevu 1, 2, 4 ili 6 naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(VII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
A2 je CH ili CZ;
R3 je opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2; i
m je 0 ili cijeli broj od 1 do 5.
8. Postupak prema zahtjevu 7, naznačen time da A2 je CH.
9. Postupak prema zahtjevu 7, naznačen time da L je -NHC(O)- ili -NHCH2-.
10. Postupak prema zahtjevu 9, naznačen time da Y je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
11. Postupak prema zahtjevu 10, naznačen time da Y je opcijski supstituiran fenil, opcijski supstituiran piridil, ili opcijski supstituiran [1,2,3]tiadiazolil.
12. Postupak prema zahtjevu 11, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(IX)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R7 i R8 su svaki, nezavisno, -H, -CF3, -CN, -C(O)CH3, -F, -Cl, -OCH3, -OCH2CH3, -C(O)OCH2CH3, -SCH3, -NHCH3, ili C1-C4 alkil, pod uvjetom da barem jedan od R7 ili R8 nije -H.
13. Postupak prema zahtjevu 12, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XI)
pri čemu:
A1 je CH, CR9, N ili N→O;
R9, za svako pojavljivanje, je, nezavisno, halo, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi, C1-C4 haloalkoksi, ili hidroksil; i
q je 0 ili cijeli broj od 1 do 5.
14. Postupak prema zahtjevu 13, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R10 i R11, su svaki, nezavisno, -F, -Cl, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi ili C1-C4 haloalkoksi.
15. Postupak prema zahtjevu 13, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XIII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R10 i R11 su svaki, nezavisno, -F, -Cl, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi i C1-C4 haloalkoksi.
16. Postupak prema zahtjevu 1, 2, 4 ili 6, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(V)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R12 i R13, za svako pojavljivanje, je, nezavisno, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
r je 0, 1 ili 2; i
s je 0 ili cijeli broj od 1 do 4.
17. Postupak prema zahtjevu 16, naznačen time da L je -NHC(O)- i Y je opcijski supstituiran fenil.
18. Postupak prema zahtjevu 17, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XIV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R14 i R15 su svaki, nezavisno, -CF3, -OCH3, -F, -Cl, ili-C(O)OCH3; i
t je 0, 1 ili 2.
19. Postupak prema zahtjevu 18, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R9, za svako pojavljivanje, je, nezavisno, halo, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi, C1-C4 haloalkoksi, ili hidroksil; i
q je 0 ili cijeli broj od 1 do 5.
20. Postupak prema zahtjevu 19, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVI)
ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu:
R16 i R17 su svaki, nezavisno, -F, ili -OCH3.
21. Postupak prema zahtjevu 19, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R16 i R17 su svaki, nezavisno, -F, ili -OCH3.
22. Postupak prema zahtjevu 1, 2, 4 ili 6, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(VI)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R3 je opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2; i
u je 0, 1, ili 2.
23. Postupak prema zahtjevu 22, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVIII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R20 i R21 su svaki, nezavisno, -H1 -F, -Cl, C1-C4 alkil, tiofenil, -OCH3, -CF3, ili -OCF3;
R9, za svako pojavljivanje, je, nezavisno, halo, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi, C1-C4 haloalkoksi, ili hidroksil; i
q je 0 ili cijeli broj od 1 do 5.
24. Postupak prema zahtjevu 1, 2, 4 ili 6 naznačen time da se na stanicu primjenjuje jedan ili više spojeva odabranih iz skupine koja sadrži:
3-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(2'-metil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(3'-trifluorometil-bifenil-4-il)-izonikotinamid;
N-(2,2'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(1,2-Dimetil-but-1-enil)-3-trifluorometil-fenil]-2,3-difluoro-benzamid;
4'-(2,3-Difluoro-benzoilamino)-bifenil-2-karboksilna kiselina dimetilamid;
N-(2'-Trifluorometil-bifenil-4-il)-nikotinamid;
N-(2'-Trifluorometil-bifenil-4-il)izonikotinamid;
Tiofen-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,4-Dimetil-tiazol-5-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Trifluorometil-N-(2'-trifluorometil-bifenil-4-il)-nikotinamid;
2-Metil-5-trifluorometil-oksazol-4-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2-Etil-5-metil-2H-pirazol-3-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2,3-Difluoro-N-(2,-trifluorometil-bifenil-4-il)-benzamid;
2,5-Difluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(3-fluoro-2'-trifluorometil-bifenil-4-il)-benzamid;
N-(2',5'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
2,3-Difluoro-N-(2'-fluoro-5'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(4,-fluoro-2'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-[4-(2- trifluorometil-indolizin-3-il)- fenil]-benzamid;
2,3-Difluoro-N-(2'-fluoro-6'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(2,-kloro-5'-trifluorometil-bifenil-4-il)-benzamid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Piridin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
Pirazin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2'-kloro-5'-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-Bis-trifluorometil- bifenil-4-il)-2,5-difluoro-benzamid;
N-(2',5'-Dikloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(5'-Cijano-2'-metoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-Dimetoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(3,5-Bis-trifluorometil-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
3-Metil-tiofen-2-karboksilna kiselina-(4-(3,5-bis-trifluorometil-[1,2,4]triazol-4-il)-fenil)-amid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-cijano-5-trifluorometil-pirid-2-il)-fenil]-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksi-benzamid;
5-Metil-izoksazol-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1,3-Dimetil-1H-pirazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
[1,2,3]-Tiadiazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Izoksazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3,5-dimetilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksibenzamid;
N-(2'-metoksi-5'-metil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-dimetil-bifenil-4-il)-2,3-difluorobenzamid;
3-Metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-hidroksibenzamid;
N-(2'-metoksi-5'-acetil-bifenil-4-il)-2,3-difluorobenzamid;
5-metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',4',5'-trimetil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,3-dimetilbenzamid;
N-(2',5'-bis- trifluorometil-bifenil-4-il)-2-metil-3-klorobenzamid;
N-(2',5'-bis-trifluorometil- bifenil-4-il)-2-metil-3-fluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metil-3-metoksibenzamid;
4-Metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2',5'-dimetoksi bifenil-4-il)-amid;
N-(2',5'-dimetoksi- bifenil-4-il)-2-metilbenzamid;
2-metil-piridin-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
2,3-dihidro-benzo[1,4]dioksin-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1-metil-1H-imidazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetoksi-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-dimetoksibifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-metilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetilbifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2'-metoksi-5'-acetilbifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-difluorometoksi-5'-klorobifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina{2'-(N,N-dimetilamino)-5'-trifluorometoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-kloro-5'-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metilsulfanil-bifenil- 4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-izopropil-bifenil-4-il)-amid;
N-{5-(2',5'-dimetoksifenil)-pirid-2-il}-2-metilbenzamid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dietilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N,N-dimetilamino)-5'-metoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N-dimetilamino)-5'-karbetoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etoksi-5'-klorobifenil-4-il)-amid;
N-(2'-dimetoksi-5'-kloro bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,4,5-trifluorobenzamid;
N-(2',5'-bis-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-kloro-5'-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dimetil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dikloro bifenil-4-il)-2,6-difluorobenzamid;
2,3-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,5-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3,4-dimetoksi-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-metoksi-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil- indolizin-7-karboksilna kiselina metil ester;
2,6-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Metoksi-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
2,6-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Metoksi-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,6-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,3-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-(2',5'-dimetoksi-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2'-trifluorometil-5'-metil-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N',N'-dietil-N-(2',5'-bis-trifluorometil bifenil-4-il) urea;
2,3-difluoro-N-[4-(2-trifluoro- metil-indolizin-3-il)-fenil]-benzamid;
4-metil-N-[4-(2-metil- indolizin-3-il)-fenil]-[1,2,3]tiadiazol 5-karboksilna kiselina amid; i
njihove farmaceutski prihvatljive soli, solvati, ili klatrati.
25. Spoj naznačen time da je predstavljen sa slijedećom strukturnom formulom (II):
[image]
(II)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y1 je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
A je -CH=CH-, -CZ=CH-, -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je cijeli broj odabran od 0-4; i
p je 0, 1, ili 2,
pod uvjetom da Y1 nije heteroaril koji je nadalje supstituiran sa supstituiranim ili nesupstituiranim arilom ili supstituiranim ili nesupstituiranim heteroarilom;
pod uvjetom da kada X je p-halofenil, p-nitrofenil, p-cijanofenil, p-(metoksimetil)fenil, p-(benzamido)fenil, supstituirani p-(benzamido)fenil, ili p-karboksifenil, Y1 nije supstituirani ili nesupstituirani fenil, nesupstituirani furil, supstituirani ili nesupstituirani tiofenil, supstituirani benzo[b]tiofenil, nesupstituirani tiazolil, supstituirani 7,8-dihidronaftil, supstituirani pirazinil, ili supstituirani ili nesupstituirani piridinil;
pod uvjetom da kada X je m-nitrofenil ili m-(trifluorometil)fenil, Y1 nije supstituirani ili nesupstituirani fenil;
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa -S(O)2NH2; i
pod uvjetom da X nije nitrofenil kada Y1 je supstituiran sa 1H-pirazolilom.
26. Spoj prema zahtjevu 25, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(VIII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
A2 je CH ili CZ;
R3 je opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2; i
m je 0 ili cijeli broj od 1 do 5.
27. Spoj prema zahtjevu 26, naznačen time da A2 je CH.
28. Spoj prema zahtjevu 26, naznačen time da L je -NHC(O)- ili -NHCH2-.
29. Spoj prema zahtjevu 28, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
30. Spoj prema zahtjevu 29, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, ili opcijski supstituiran [1,2,3]tiadiazolil.
31. Spoj prema zahtjevu 30, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(X)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R7 i R8 su svaki, nezavisno, -H, -CF3, -CN, -C(O)CH3, -F, -Cl, -OCH3, -OCH2CH3, -C(O)OCH2CH3, -SCH3, -NHCH3, ili C1-C4 alkil, pod uvjetom da barem jedan od R7 ili R8 nije -H.
32. Spoj naznačen time da je predstavljen sa slijedećom strukturnom formulom:
[image]
(III)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y2 je opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, ili opcijski supstituiran heterociklil;
A je -CH=CH-, -CZ=CH-, -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4; i
p je 0, 1, ili 2,
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa –CN ili -S(O)2NH2;
pod uvjetom da Y2 nije 4,5-dihidroizoksazlil koji je nadalje supstituiran sa supstituiranim ili nesupstituiranim arilom ili supstituiranim ili nesupstituiranim heteroarilom; i
pod uvjetom da Y2 nije supstituirani ciklopentenil.
33. Spoj naznačen time da je odabran iz skupine koja sastoji od:
3-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(2'-metil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(3'-trifluorometil-bifenil-4-il)-izonikotinamid;
N-(2,2'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(1,2-Dimetil-but-1-enil)-3-trifluorometil-fenil]-2,3-difluoro-benzamid;
4'-(2,3-Difluoro-benzoilamino)-bifenil-2-karboksilna kiselina dimetilamid;
N-(2'-Trifluorometil-bifenil-4-il)-nikotinamid;
N-(2'-Trifluorometil-bifenil-4-il)izonikotinamid;
Tiofen-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,4-Dimetil-tiazol-5-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Trifluorometil-N-(2'-trifluorometil-bifenil-4-il)-nikotinamid;
2-Metil-5-trifluorometil-oksazol-4-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2-Etil-5-metil-2H-pirazol-3-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2,3-Difluoro-N-(2,-trifluorometil-bifenil-4-il)-benzamid;
2,5-Difluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(3-fluoro-2'-trifluorometil-bifenil-4-il)-benzamid;
N-(2',5'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
2,3-Difluoro-N-(2'-fluoro-5'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(4,-fluoro-2'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-[4-(2- trifluorometil-indolizin-3-il)- fenil]-benzamid;
2,3-Difluoro-N-(2'-fluoro-6'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(2,-kloro-5'-trifluorometil-bifenil-4-il)-benzamid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Piridin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
Pirazin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2'-kloro-5'-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-Bis-trifluorometil- bifenil-4-il)-2,5-difluoro-benzamid;
N-(2',5'-Dikloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(5'-Cijano-2'-metoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-Dimetoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(3,5-Bis-trifluorometil-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
3-Metil-tiofen-2-karboksilna kiselina-(4-(3,5-bis-trifluorometil-[1,2,4]triazol-4-il)-fenil)-amid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-cijano-5-trifluorometil-pirid-2-il)-fenil]-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksi-benzamid;
5-Metil-izoksazol-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1,3-Dimetil-1H-pirazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
[1,2,3]-Tiadiazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Izoksazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3,5-dimetilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksibenzamid;
N-(2'-metoksi-5'-metil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-dimetil-bifenil-4-il)-2,3-difluorobenzamid;
3-Metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-hidroksibenzamid;
N-(2'-metoksi-5'-acetil-bifenil-4-il)-2,3-difluorobenzamid;
5-metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',4',5'-trimetil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,3-dimetilbenzamid;
N-(2',5'-bis- trifluorometil-bifenil-4-il)-2-metil-3-klorobenzamid;
N-(2',5'-bis-trifluorometil- bifenil-4-il)-2-metil-3-fluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metil-3-metoksibenzamid;
4-Metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2',5'-dimetoksi bifenil-4-il)-amid;
N-(2',5'-dimetoksi- bifenil-4-il)-2-metilbenzamid;
2-metil-piridin-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
2,3-dihidro-benzo[1,4]dioksin-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1-metil-1H-imidazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetoksi-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-dimetoksibifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-metilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetilbifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2'-metoksi-5'-acetilbifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-difluorometoksi-5'-klorobifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina{2'-(N,N-dimetilamino)-5'-trifluorometoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-kloro-5'-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metilsulfanil-bifenil- 4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-izopropil-bifenil-4-il)-amid;
N-{5-(2',5'-dimetoksifenil)-pirid-2-il}-2-metilbenzamid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dietilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N,N-dimetilamino)-5'-metoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N-dimetilamino)-5'-karbetoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etoksi-5'-klorobifenil-4-il)-amid;
N-(2'-dimetoksi-5'-kloro bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,4,5-trifluorobenzamid;
N-(2',5'-bis-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-kloro-5'-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dimetil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dikloro bifenil-4-il)-2,6-difluorobenzamid;
2,3-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,5-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3,4-dimetoksi-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-metoksi-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil- indolizin-7-karboksilna kiselina metil ester;
2,6-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Metoksi-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
2,6-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Metoksi-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,6-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,3-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-(2',5'-dimetoksi-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2'-trifluorometil-5'-metil-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N',N'-dietil-N-(2',5'-bis-trifluorometil bifenil-4-il) urea;
2,3-difluoro-N-[4-(2-trifluoro- metil-indolizin-3-il)-fenil]-benzamid;
4-metil-N-[4-(2-metil- indolizin-3-il)-fenil]-[1,2,3]tiadiazol 5-karboksilna kiselina amid; i
njihove farmaceutski prihvatljive soli, solvati, ili klatrati.
34. Spoj naznačen time da je predstavljen sa slijedećom strukturnom formulom:
[image]
(IV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Z, R3 i R22, za svako pojavljivanje, su, nezavisno, odabrani iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži -NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4;
m i q su svaki nezavisno, 0 ili cijeli broj od 1 do 5; i
p je 0,1, ili 2,
pod uvjetom da kada X je p-halofenil, p-nitrofenil, p-cijanofenil, p-(metoksimetil)fenil, p-(benzamido)fenil, supstituirani p- (benzamido)fenil, ili p-karboksifenil, Y nije supstituirani ili nesupstituirani fenil, nesupstituirani furil, supstituirani ili nesupstituirani tiofenil, supstituirani benzo[b]tiofenil, nesupstituirani tiazolil, supstituirani 7,8-dihidronaftil, supstituirani pirazinil, ili supstituirani ili nesupstituirani piridinil;
pod uvjetom da kada X je m-nitrofenil ili m-(trifluorometil)fenil, Y1 nije supstituirani ili nesupstituirani fenil; i
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa -S(O)2NH2.
35. Spoj naznačen time da je predstavljen sa slijedećom strukturnom formulom:
[image]
(V)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
Z, R12 i R13, za svako pojavljivanje, je, nezavisno, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
r je 0, 1 ili 2;
n i s su svaki, nezavisno, 0 ili cijeli broj od 1 do 4; i
p je 0, 1 ili 2.
36. Spoj prema zahtjevu 35, naznačen time da L je -NHC(O)- i Y je opcijski supstituiran fenil.
37. Spoj prema zahtjevu 36, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XIV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R14 i R15 su svaki, nezavisno, -CF3, -OCH3, -F, -Cl, ili - C(O)OCH3; i
t je 0, 1 ili 2.
38. Spoj prema zahtjevu 37, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R9, za svako pojavljivanje, je, nezavisno, halo, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi, C1-C4 haloalkoksi, ili hidroksil; i
q je 0 ili cijeli broj od 1 do 5.
39. Spoj prema zahtjevu 38, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVI)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R16 i R17 su svaki, nezavisno, -F1 ili -OCH3.
40. Spoj prema zahtjevu 38, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVII)
ili farmaceutski prihvatljiva sol, solvat, ili njihov klatrat naznačen time da
R16 i R17 su svaki, nezavisno, -F, ili -OCH3.
41. Spoj naznačen time da je predstavljen sa slijedećom strukturnom formulom:
[image]
(VI)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
Z i R3, za svako pojavljivanje, su, nezavisno, odabrani iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je cijeli broj odabran od 0-4;
p je 0, 1, ili 2; i
u je 0,1, ili 2.
42. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva predstavljenih sa slijedećom strukturnom formulom:
[image]
(II)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y1 je opcijski supstituiran aril ili opcijski supstituiran heteroaril;
A je -CH=CH-, -CZ=CH-, -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H1 alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je cijeli broj odabran od 0-4; i
p je 0, 1, ili 2,
pod uvjetom da Y1 nije heteroaril koji je nadalje supstituiran sa supstituiranim ili nesupstituiranim arilom ili supstituiranim ili nesupstituiranim heteroarilom;
pod uvjetom da kada X je p-halofenil, p-nitrofenil, p-cijanofenil, p-(metoksimetil)fenil, p-(benzamido)fenil, supstituirani p-(benzamido)fenil, ili p-karboksifenil, Y1 nije supstituirani ili nesupstituirani fenil, nesupstituirani furil, supstituirani ili nesupstituirani tiofenil, supstituirani benzo[b]tiofenil, nesupstituirani tiazolil, supstituirani 7,8- dihidronaftil, supstituirani pirazinil, ili supstituirani ili nesupstituirani piridinil;
pod uvjetom da kada X je m-nitrofenil ili m-(trifluorometil)fenil, Y1 nije supstituirani ili nesupstituirani fenil;
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa -S(O)2NH2; i
pod uvjetom da X nije nitrofenil kada Y1 je supstituiran sa 1H-pirazolilom.
43. Farmaceutski pripravak prema zahtjevu 42, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(VIII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
A2 je CH ili CZ;
R3 je opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2; i
m je 0 ili cijeli broj od 1 do 5.
44. Farmaceutski pripravak prema zahtjevu 43, naznačen time da A2 je CH.
45. Farmaceutski pripravak prema zahtjevu 43, naznačen time da L je -NHC(O)- ili -NHCH2-.
46. Farmaceutski pripravak prema zahtjevu 45, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
47. Farmaceutski pripravak prema zahtjevu 46, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, ili opcijski supstituiran [1,2,3]tiadiazolil.
48. Farmaceutski pripravak prema zahtjevu 47, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(X)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R7 i R8 su svaki, nezavisno, -H, -CF3, -CN, -C(O)CH3, -F, -Cl, -OCH3, -OCH2CH3, -C(O)OCH2CH3, -SCH3, -NHCH3, ili C1-C4 alkil, pod uvjetom da barem jedan od R7 ili R8 nije -H.
49. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva predstavljenih sa slijedećom strukturnom formulom:
[image]
(III)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
Y2 je opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, ili opcijski supstituiran heterociklil;
A je -CH=CH-, -CZ=CH-, -CH=CZ-;
svaki Z je nezavisno odabran iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4; i
p je 0, 1, ili 2,
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa –CN ili -S(O)2NH2;
pod uvjetom da Y2 nije 4,5-dihidroizoksazlil koji je nadalje supstituiran sa supstituiranim ili nesupstituiranim arilom ili supstituiranim ili nesupstituiranim heteroarilom; i
pod uvjetom da Y2 nije supstituirani ciklopentenil.
50. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva odabranih iz skupine koja sadrži:
3-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(2'-metil-bifenil-4-il)-izonikotinamid;
3-Fluoro-N-(3'-trifluorometil-bifenil-4-il)-izonikotinamid;
N-(2,2'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(1,2-Dimetil-but-1-enil)-3-trifluorometil-fenil]-2,3-difluoro-benzamid;
4'-(2,3-Difluoro-benzoilamino)-bifenil-2-karboksilna kiselina dimetilamid;
N-(2'-Trifluorometil-bifenil-4-il)-nikotinamid;
N-(2'-Trifluorometil-bifenil-4-il)izonikotinamid;
Tiofen-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,4-Dimetil-tiazol-5-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Trifluorometil-N-(2'-trifluorometil-bifenil-4-il)-nikotinamid;
2-Metil-5-trifluorometil-oksazol-4-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2-Etil-5-metil-2H-pirazol-3-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
2,3-Difluoro-N-(2,-trifluorometil-bifenil-4-il)-benzamid;
2,5-Difluoro-N-(2'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(3-fluoro-2'-trifluorometil-bifenil-4-il)-benzamid;
N-(2',5'-Bis-trifluorometil-bifenil-4-il)-2,3-difluoro-benzamid;
2,3-Difluoro-N-(2'-fluoro-5'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(4,-fluoro-2'- trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-[4-(2- trifluorometil-indolizin-3-il)- fenil]-benzamid;
2,3-Difluoro-N-(2'-fluoro-6'-trifluorometil-bifenil-4-il)-benzamid;
2,3-Difluoro-N-(2,-kloro-5'-trifluorometil-bifenil-4-il)-benzamid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Piridin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
Pirazin-2-karboksilna kiselina (2'-trifluorometil-bifenil-4-il)-amid;
4-Metil-[1,2,3]tiadiazol-5-karboksilna kiselina (2'-kloro-5'-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-Bis-trifluorometil- bifenil-4-il)-2,5-difluoro-benzamid;
N-(2',5'-Dikloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(5'-Cijano-2'-metoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-Dimetoksi-bifenil-4-il)-2,3-difluoro-benzamid;
N-[4-(3,5-Bis-trifluorometil-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
3-Metil-tiofen-2-karboksilna kiselina-(4-(3,5-bis-trifluorometil-[1,2,4]triazol-4-il)-fenil)-amid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-5-(tiofen-4-il)-[1,2,4]triazol-4-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(3-cijano-5-trifluorometil-pirid-2-il)-fenil]-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksi-benzamid;
5-Metil-izoksazol-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1,3-Dimetil-1H-pirazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
[1,2,3]-Tiadiazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
Izoksazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3,5-dimetilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,3-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metoksibenzamid;
N-(2'-metoksi-5'-metil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-dimetil-bifenil-4-il)-2,3-difluorobenzamid;
3-Metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-hidroksibenzamid;
N-(2'-metoksi-5'-acetil-bifenil-4-il)-2,3-difluorobenzamid;
5-metilizoksazol-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
N-(2',4',5'-trimetil-bifenil-4-il)-2,3-difluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,3-dimetilbenzamid;
N-(2',5'-bis- trifluorometil-bifenil-4-il)-2-metil-3-klorobenzamid;
N-(2',5'-bis-trifluorometil- bifenil-4-il)-2-metil-3-fluorobenzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2-metil-3-metoksibenzamid;
4-Metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2',5'-dimetoksi bifenil-4-il)-amid;
N-(2',5'-dimetoksi- bifenil-4-il)-2-metilbenzamid;
2-metil-piridin-3-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
2,3-dihidro-benzo[1,4]dioksin-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
1-metil-1H-imidazol-5-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetoksi-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-dimetoksibifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-metoksi-5'-klorobifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2',5'-bis-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metoksi-5'-metilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dimetilbifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina (2'-metoksi-5'-acetilbifenil-4-il)-amid;
3-fluoro-piridin-4-karboksilna kiselina (2'-difluorometoksi-5'-klorobifenil-4-il)-amid;
4-metil-[1,2,3]-tiadiazol-5-karboksilna kiselina{2'-(N,N-dimetilamino)-5'-trifluorometoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-kloro-5'-trifluorometilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-metilsulfanil-bifenil- 4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etil-bifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina (2'-izopropil-bifenil-4-il)-amid;
N-{5-(2',5'-dimetoksifenil)-pirid-2-il}-2-metilbenzamid;
3-metil-piridin-4-karboksilna kiselina (2',5'-dietilbifenil-4-il)-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N,N-dimetilamino)-5'-metoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina {2'-(N-dimetilamino)-5'-karbetoksibifenil-4-il}-amid;
3-metil-piridin-4-karboksilna kiselina (2'-etoksi-5'-klorobifenil-4-il)-amid;
N-(2'-dimetoksi-5'-kloro bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,4,5-trifluorobenzamid;
N-(2',5'-bis-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2'-kloro-5'-trifluorometil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dimetil bifenil-4-il)-2,6-difluorobenzamid;
N-(2',5'-dikloro bifenil-4-il)-2,6-difluorobenzamid;
2,3-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,5-Difluoro-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3,4-dimetoksi-N-[4-(2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,3-difluoro-benzamid;
5-metoksi-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,3-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,3-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil- indolizin-7-karboksilna kiselina metil ester;
2,6-difluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Metoksi-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
2,6-difluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
5-Kloro-3-[4-(2,6-difluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,6-difluoro-benzamid;
N-[4-(5-Kloro-2-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(5-fluoro-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(6-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,4,5-trifluoro-N-[4-(5-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-[4-(5-Kloro-2,7-bis-trifluorometil-indolizin-3-il)-fenil]-2,4,5-trifluoro-benzamid;
5-Metoksi-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-6-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(8-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
5-Kloro-3-[4-(2,4,5-trifluoro-benzoilamino)-fenil]-2-trifluorometil-indolizin-7-karboksilna kiselina metil ester;
2,4,5-trifluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,6-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
2,3-difluoro-N-[4-(7-metoksi-2-trifluorometil-indolizin-3-il)-fenil]-benzamid;
N-(2',5'-dimetoksi-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2'-trifluorometil-5'-metil-bifenil-4-il)-2,6-difluoro-benzamid;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2',5'-bis-trifluorometil-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin;
N-(2'-metoksi-5'-kloro-bifenil-4-il)-2,6-difluoro-benzil amin HCl sol;
N',N'-dietil-N-(2',5'-bis-trifluorometil bifenil-4-il) urea;
2,3-difluoro-N-[4-(2-trifluoro- metil-indolizin-3-il)-fenil]-benzamid;
4-metil-N-[4-(2-metil- indolizin-3-il)-fenil]-[1,2,3]tiadiazol 5-karboksilna kiselina amid; i
njegove farmaceutski prihvatljive soli, solvati ili klatrati.
51. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva predstavljenih sa slijedećom strukturnom formulom:
[image]
(IV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Z, R3 i R22 za svako pojavljivanje, su, nezavisno, odabrani iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je 0 ili cijeli broj od 1 do 4;
m i q su svaki nezavisno, 0 ili cijeli broj od 1 do 5; i
p je 0, 1, ili 2,
pod uvjetom da kada X je p-halofenil, p-nitrofenil, p-cijanofenil, p-(metoksimetil)fenil, p-(benzamido)fenil, supstituirani p- (benzamido)fenil, ili p-karboksifenil, Y nije supstituirani ili nesupstituirani fenil, nesupstituirani furil, supstituirani ili nesupstituirani tiofenil, supstituirani benzo[b]tiofenil, nesupstituirani tiazolil, nesupstituirani 7,8-dihidronaftil, supstituirani pirazinil, ili supstituirani ili nesupstituirani piridinil;
pod uvjetom da kada X je m-nitrofenil ili m-(trifluorometil)fenil, Y1 nije supstituirani ili nesupstituirani fenil; i
pod uvjetom da X nije fenil koji je supstituiran na orto položaju sa -S(O)2NH2.
52. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva predstavljenih sa slijedećom strukturnom formulom:
[image]
(V)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
Z, R12 i R13, za svako pojavljivanje, je, nezavisno, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NR1R2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
r je 0, 1 ili 2;
n i s su svaki, nezavisno, 0 ili cijeli broj od 1 do 4; i
p je 0, 1 ili 2.
53. Farmaceutski pripravak prema zahtjevu 52, naznačen time da L je -NHC(O)- i Y je opcijski supstituiran fenil.
54. Farmaceutski pripravak prema zahtjevu 53, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XIV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R14 i R15 su svaki, nezavisno, -CF3, -OCH3, -F, -Cl, ili -C(O)OCH3; i
t je 0, 1 ili 2.
55. Farmaceutski pripravak prema zahtjevu 54, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XV)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R9, za svako pojavljivanje, je, nezavisno, halo, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi, C1-C4 haloalkoksi, ili hidroksil; i
q je 0 ili cijeli broj od 1 do 5.
56. Farmaceutski pripravak prema zahtjevu 55, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVI)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R16 i R17 su svaki, nezavisno, -F1 ili -OCH3.
57. Farmaceutski pripravak prema zahtjevu 55, naznačen time da je spoj predstavljen sa slijedećom strukturnom formulom:
[image]
(XVII)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
R16 i R17 su svaki, nezavisno, -F, ili -OCH3.
58. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva predstavljenih sa slijedećom strukturnom formulom:
[image]
(VI)
ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu:
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, C1-C4 alkila, halogeniranog C1-C4 alkila, ili C1-C4 alkoksi;
Z i R3, za svako pojavljivanje, su, nezavisno, odabrani iz skupine koja sadrži opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, opcijski supstituiran heteraralkil, haloalkil, -C(O)NR1R2, -NR4C(O)R5, halo, -OR4, cijano, nitro, haloalkoksi, -C(O)R4, -NRiR2, -SR4, -C(O)OR4, -OC(O)R4, -NR4C(O)NR1R2, -OC(O)NR1R2, -NR4C(O)OR5, -S(O)pR4, ili -S(O)pNR1R2;
L je poveznik odabran iz skupine koja sadrži-NRCH2-, i -NR-C(O)-;
svaki R je nezavisno odabran od -H, alkila, acetila, terc-butoksikarbonila, benziloksikarbonila;
R1 i R2, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R1 i R2 uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
R4 i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
n je cijeli broj odabran od 0-4;
p je 0, 1, ili 2; i
u je 0, 1, ili 2.
59. Farmaceutski pripravak prema zahtjevu 40, 49, 50, 51, 52 ili 58, naznačen time da nadalje sadrži jedno ili više dodatnih terapeutskih sredstava.
60. Farmaceutski pripravak prema zahtjevu 59, naznačen time da je dodatno terapeutsko sredstvo je odabrano iz skupine koja sadrži imunosupresivna sredstva i protuupalna sredstva i njihove pogodne mješavine.
61. Farmaceutski pripravak prema zahtjevu 60, naznačen time da je dodatno terapeutsko sredstvo je odabrano iz skupine koja sadrži steroide, ne-steroidna protuupalna sredstva, antihistaminike, analgetike, i njihove pogodne mješavine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48971103P | 2003-07-23 | 2003-07-23 | |
PCT/US2004/023895 WO2005009539A2 (en) | 2003-07-23 | 2004-07-22 | Compounds for inflammation and immune-related uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110180T1 true HRP20110180T1 (hr) | 2011-04-30 |
Family
ID=34102928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110180T HRP20110180T1 (hr) | 2003-07-23 | 2011-03-11 | Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet |
Country Status (25)
Country | Link |
---|---|
US (3) | US20050107436A1 (hr) |
EP (3) | EP1651232B1 (hr) |
JP (4) | JP4979378B2 (hr) |
KR (2) | KR101245062B1 (hr) |
CN (4) | CN1826121B (hr) |
AT (1) | ATE492278T1 (hr) |
AU (3) | AU2004259347B2 (hr) |
BR (2) | BRPI0412257A (hr) |
CA (2) | CA2533598C (hr) |
CY (1) | CY1112214T1 (hr) |
DE (1) | DE602004030689D1 (hr) |
DK (1) | DK1651232T3 (hr) |
ES (1) | ES2358426T3 (hr) |
HK (1) | HK1089973A1 (hr) |
HR (1) | HRP20110180T1 (hr) |
IL (2) | IL173270A0 (hr) |
MX (2) | MXPA06000837A (hr) |
NO (2) | NO20060408L (hr) |
NZ (2) | NZ587056A (hr) |
PL (1) | PL1651232T3 (hr) |
PT (1) | PT1651232E (hr) |
SI (1) | SI1651232T1 (hr) |
TW (2) | TWI332832B (hr) |
WO (2) | WO2005009954A2 (hr) |
ZA (2) | ZA200601559B (hr) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538697A (ja) * | 2002-04-19 | 2005-12-22 | シエーリング アクチエンゲゼルシャフト | 新規前立腺腫瘍特異的プロモーター |
DE602004030689D1 (de) * | 2003-07-23 | 2011-02-03 | Synta Pharmaceuticals Corp | Verbindungen gegen entzündungen und immun-relevante verwendungen |
BRPI0412918A (pt) * | 2003-07-25 | 2006-09-26 | Novartis Ag | inibidores de quinases p38 |
TWI359017B (en) * | 2003-11-10 | 2012-03-01 | Synta Pharmaceuticals Corp | Heteroaryl-hydrazone compounds |
BRPI0606476A2 (pt) | 2005-01-07 | 2009-06-30 | Synta Pharmaceuticals Corp | compostos para inflamação e usos imuno-relacionados e suas composições farmacêuticas |
NZ556732A (en) * | 2005-01-25 | 2011-11-25 | Synta Pharmaceuticals Corp | Pyrazine compounds for inflammation and immune-related uses |
JP5221147B2 (ja) * | 2005-01-25 | 2013-06-26 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
EP1910367A2 (en) * | 2005-05-20 | 2008-04-16 | Alantos Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
CN101360738A (zh) * | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
JP2009524677A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
AU2007208151B2 (en) * | 2006-01-25 | 2013-04-18 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
JP2009524678A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連用途のためのフェニル及びピリジル化合物 |
WO2007087441A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
US8623871B2 (en) * | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
PL1984338T3 (pl) * | 2006-01-31 | 2013-06-28 | Synta Pharmaceuticals Corp | Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością |
WO2007109362A2 (en) * | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
PE20080176A1 (es) | 2006-03-31 | 2008-04-25 | Glaxo Group Ltd | Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) |
AU2007238225A1 (en) * | 2006-04-10 | 2007-10-25 | Beth Israel Deaconess Medical Center | CRAC modulators and use of same for drug discovery |
WO2007147794A1 (en) * | 2006-06-19 | 2007-12-27 | Smithkline Beecham Corporation | Furan derivatives and their use as antiviral agents |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
JP2010509392A (ja) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
AU2007323541B2 (en) * | 2006-11-21 | 2012-01-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a GM-CSF antagonist |
WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
CN103450077B (zh) | 2007-06-08 | 2016-07-06 | 满康德股份有限公司 | IRE-1α抑制剂 |
TW200914440A (en) * | 2007-08-01 | 2009-04-01 | Synta Pharmaceuticals Corp | Vinyl-aryl derivatives for inflammation and immune-related uses |
TW200911800A (en) * | 2007-08-01 | 2009-03-16 | Synta Pharmaceuticals Corp | Pyridine compounds for inflammation and immune-related uses |
US9024009B2 (en) | 2007-09-10 | 2015-05-05 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
MX2010002712A (es) | 2007-09-10 | 2010-06-09 | Calcimedica Inc | Compuestos que modulan calcio intracelular. |
US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2321303B1 (en) | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
EP2400964A4 (en) * | 2009-01-30 | 2012-08-01 | Glaxosmithkline Llc | CRYSTALLINE FORM OF N - {(1-5) -2-AMINO-1 - [(3-FLUOROPHENYL) METHYL] ETHYL} -5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PYRAZOL) CHLOROHYDRATE 5-YL) -2-THIOPHENE CARBOXAMIDE |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
DK2451797T3 (da) | 2009-07-10 | 2013-06-24 | Janssen Pharmaceutica Nv | Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen |
EP2477982A4 (en) | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
SG10201500258WA (en) | 2009-10-14 | 2015-03-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US20120231006A1 (en) | 2009-11-20 | 2012-09-13 | Amgen Inc. | Anti-orai1 antigen binding proteins and uses thereof |
ES2591004T3 (es) | 2010-04-27 | 2016-11-24 | Calcimedica, Inc. | Compuestos moduladores del calcio intracelular |
CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
KR101931209B1 (ko) | 2010-05-11 | 2018-12-20 | 얀센 파마슈티카 엔.브이. | Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형 |
EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
EP3067347A1 (en) * | 2010-10-30 | 2016-09-14 | Lupin Limited | Oxazoline and isoxazoline derivatives as crac modulators |
JP5973551B2 (ja) | 2011-04-13 | 2016-08-23 | ヤンセン ファーマシューティカ エヌ.ベー. | Sglt2の阻害物質として有用な化合物の調製プロセス |
CA2834928C (en) | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9522873B2 (en) | 2011-08-05 | 2016-12-20 | Dongguk University Industry-Academic Cooperation Foundation | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases |
EA026702B1 (ru) | 2011-09-16 | 2017-05-31 | Санофи | Производные анилина, их получение и терапевтическое применение |
WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9399638B2 (en) | 2012-05-02 | 2016-07-26 | Lupin Limited | Substituted pyridine compounds as CRAC modulators |
CA2871222A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
MX2014014614A (es) | 2012-05-31 | 2015-02-12 | Phenex Pharmaceuticals Ag | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma). |
WO2014043715A1 (en) * | 2012-09-17 | 2014-03-20 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
AR094411A1 (es) | 2013-01-10 | 2015-07-29 | Gruenenthal Gmbh | Carboxamidas basadas en pirazolilo ii |
CN104994851A (zh) | 2013-01-10 | 2015-10-21 | 格吕伦塔尔有限公司 | 作为crac通道抑制剂的基于吡唑基的甲酰胺i |
CA2914132A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
AU2014300629A1 (en) | 2013-06-24 | 2015-12-24 | Lupin Limited | Chromane and chromene derivatives and their use as CRAC modulators |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
WO2015187827A1 (en) * | 2014-06-03 | 2015-12-10 | The Trustees Of The University Of Pennsylvania | Novel effective antiviral compounds and methods using same |
WO2015197187A1 (en) | 2014-06-24 | 2015-12-30 | Grünenthal GmbH | Pyrazolyl-based carboxamides v |
WO2016138472A1 (en) | 2015-02-27 | 2016-09-01 | Calcimedica, Inc. | Pancreatitis treatment |
US20180161388A1 (en) | 2015-05-18 | 2018-06-14 | Beth Israel Deaconess Medical Center, Inc. | Substance p, mast cell degranulation inhibitors, and peripheral neuropathy |
EP3331525B1 (en) | 2015-08-07 | 2020-10-07 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
KR20210062023A (ko) | 2018-09-14 | 2021-05-28 | 리젠 파마슈티컬스 아게 | Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법 |
IT202000003692A1 (it) | 2020-02-21 | 2021-08-21 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Composti bifenilici come modulatori di soce, loro composizioni e usi |
US20230110180A1 (en) * | 2021-05-07 | 2023-04-13 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4710515A (en) * | 1987-03-17 | 1987-12-01 | Riker Laboratories, Inc. | Substituted biphenyl derivatives |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
GB2276161A (en) * | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
US5348948A (en) | 1993-05-07 | 1994-09-20 | American Cyanamid Company | 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
EP0832069B1 (en) * | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
US6001879A (en) | 1995-08-30 | 1999-12-14 | Bayer Aktiengesellschaft | Acylaminosalicylic acid amides and their uses as pesticides |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
ATE236890T1 (de) * | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
AU7976998A (en) * | 1997-06-19 | 1999-01-04 | Du Pont Merck Pharmaceutical Company, The | (amidino)6-membered aromatics as factor xa inhibitors |
EA200000048A1 (ru) * | 1997-06-19 | 2000-08-28 | Дюпон Фармасьютикалз Компани | ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ |
US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
IL136637A0 (en) * | 1997-12-22 | 2001-06-14 | Du Pont Pharm Co | Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors |
HUP0102782A3 (en) * | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
KR20020069183A (ko) * | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
JP2003523356A (ja) * | 2000-01-29 | 2003-08-05 | エルジー シーアイ リミテッド | アリール−アミジンを持つXa因子阻害剤とその誘導体、及びそれらのプロドラッグ |
FR2805223B1 (fr) | 2000-02-22 | 2002-06-21 | Ecia Equip Composants Ind Auto | Agencement de planche de bord de vehicule automobile |
MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
CN1440383A (zh) * | 2000-04-28 | 2003-09-03 | 三共株式会社 | PPARγ调制剂 |
AU2001268711A1 (en) * | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
JP4083422B2 (ja) * | 2000-12-22 | 2008-04-30 | 石原産業株式会社 | アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤 |
KR20030064852A (ko) * | 2000-12-22 | 2003-08-02 | 이시하라 산교 가부시끼가이샤 | 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제 |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
TW200403223A (en) | 2002-02-15 | 2004-03-01 | Glaxo Group Ltd | Novel compounds |
AU2003257541A1 (en) * | 2002-08-27 | 2004-03-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel crystals |
EP1575918A2 (en) * | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
DE602004030689D1 (de) * | 2003-07-23 | 2011-02-03 | Synta Pharmaceuticals Corp | Verbindungen gegen entzündungen und immun-relevante verwendungen |
US20050165015A1 (en) * | 2004-01-23 | 2005-07-28 | Ncube Mghele V. | Vanilloid receptor ligands and their use in treatments |
-
2004
- 2004-07-22 DE DE602004030689T patent/DE602004030689D1/de active Active
- 2004-07-22 JP JP2006521290A patent/JP4979378B2/ja not_active Expired - Fee Related
- 2004-07-22 SI SI200431630T patent/SI1651232T1/sl unknown
- 2004-07-22 AT AT04786102T patent/ATE492278T1/de active
- 2004-07-22 WO PCT/US2004/023797 patent/WO2005009954A2/en not_active Application Discontinuation
- 2004-07-22 CN CN2004800211524A patent/CN1826121B/zh not_active Expired - Fee Related
- 2004-07-22 CN CN2010102625837A patent/CN101947218A/zh active Pending
- 2004-07-22 PT PT04786102T patent/PT1651232E/pt unknown
- 2004-07-22 EP EP04786102A patent/EP1651232B1/en active Active
- 2004-07-22 TW TW093121850A patent/TWI332832B/zh not_active IP Right Cessation
- 2004-07-22 JP JP2006521279A patent/JP4979377B2/ja not_active Expired - Fee Related
- 2004-07-22 ES ES04786102T patent/ES2358426T3/es active Active
- 2004-07-22 MX MXPA06000837A patent/MXPA06000837A/es active IP Right Grant
- 2004-07-22 WO PCT/US2004/023895 patent/WO2005009539A2/en active Application Filing
- 2004-07-22 CN CN2012101695225A patent/CN102793692A/zh active Pending
- 2004-07-22 AU AU2004259347A patent/AU2004259347B2/en not_active Ceased
- 2004-07-22 TW TW093121849A patent/TWI376370B/zh not_active IP Right Cessation
- 2004-07-22 EP EP04779033A patent/EP1653968A4/en not_active Withdrawn
- 2004-07-22 AU AU2004259024A patent/AU2004259024B2/en not_active Ceased
- 2004-07-22 NZ NZ587056A patent/NZ587056A/en not_active IP Right Cessation
- 2004-07-22 CA CA2533598A patent/CA2533598C/en not_active Expired - Fee Related
- 2004-07-22 US US10/897,681 patent/US20050107436A1/en not_active Abandoned
- 2004-07-22 BR BRPI0412257-7A patent/BRPI0412257A/pt not_active IP Right Cessation
- 2004-07-22 US US10/897,682 patent/US20050148633A1/en not_active Abandoned
- 2004-07-22 CA CA2533594A patent/CA2533594C/en not_active Expired - Fee Related
- 2004-07-22 KR KR1020067001589A patent/KR101245062B1/ko not_active IP Right Cessation
- 2004-07-22 EP EP10075464A patent/EP2319516A1/en not_active Withdrawn
- 2004-07-22 PL PL04786102T patent/PL1651232T3/pl unknown
- 2004-07-22 MX MXPA06000836A patent/MXPA06000836A/es active IP Right Grant
- 2004-07-22 KR KR1020067001588A patent/KR20060058092A/ko active IP Right Grant
- 2004-07-22 DK DK04786102.6T patent/DK1651232T3/da active
- 2004-07-22 CN CNA200480021151XA patent/CN1826120A/zh active Pending
- 2004-07-22 NZ NZ545447A patent/NZ545447A/en not_active IP Right Cessation
- 2004-07-22 BR BRPI0412805-2A patent/BRPI0412805A/pt not_active IP Right Cessation
-
2006
- 2006-01-19 IL IL173270A patent/IL173270A0/en unknown
- 2006-01-19 IL IL173269A patent/IL173269A0/en unknown
- 2006-01-25 NO NO20060408A patent/NO20060408L/no not_active Application Discontinuation
- 2006-01-25 NO NO20060409A patent/NO20060409L/no not_active Application Discontinuation
- 2006-02-22 ZA ZA200601559A patent/ZA200601559B/en unknown
- 2006-02-22 ZA ZA200601560A patent/ZA200601560B/en unknown
- 2006-10-27 HK HK06111889.5A patent/HK1089973A1/xx not_active IP Right Cessation
-
2011
- 2011-02-03 AU AU2011200458A patent/AU2011200458A1/en not_active Abandoned
- 2011-03-11 HR HR20110180T patent/HRP20110180T1/hr unknown
- 2011-03-22 CY CY20111100316T patent/CY1112214T1/el unknown
- 2011-08-12 JP JP2011177347A patent/JP2011252014A/ja active Pending
- 2011-08-12 JP JP2011177345A patent/JP2012025751A/ja active Pending
-
2013
- 2013-09-27 US US14/040,310 patent/US20150005320A9/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110180T1 (hr) | Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet | |
ES2277142T3 (es) | Compuesto de dibencilamina y su uso medicinal. | |
JP5084839B2 (ja) | チアゾール及びオキサゾール置換アリールアミド | |
ES2275887T3 (es) | Moduladores de receptores activados por proliferadores de peroxisoma (ppar). | |
ES2290486T3 (es) | Derivados de bifenilo sustituidos con heteroarilo como inhibidores de la quinasa p38. | |
JP2009525285A5 (hr) | ||
ES2450891T3 (es) | Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3 | |
RU2010140668A (ru) | Ингибиторы активности протеинтирозинкиназы | |
JP2009528273A5 (hr) | ||
JP2007519619A5 (hr) | ||
JP2013542220A5 (ja) | Crac調節剤としてのオキサゾリン及びイソキサゾリン誘導体 | |
HRP20100433T1 (hr) | Diazaindol-dikarbonil-piperazinil antivirotici | |
KR20140018997A (ko) | 염증 및 면역 관련 용도를 위한 화합물 | |
HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
JP2009529557A5 (hr) | ||
CA2417148A1 (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
WO1996033179A1 (en) | Thioamides derivates and their use as inhibitors of hyper-proliferative cell growth | |
CA2814768A1 (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
WO2005012280A1 (en) | Alkynyl aryl carboxamides | |
RU2003118718A (ru) | Производные дигидронафталина и лекарственное средство, включающее указанные производные в качестве активного ингредиента | |
CA2685952A1 (en) | N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain | |
RU2013112560A (ru) | Ингибиторы васе для применения в лечении диабета | |
AU662939B2 (en) | Nitroxyalkylamide derivatives | |
KR950700272A (ko) | 시클로헥사논 옥심 에테르, 그의 제조 방법과 제초제로서의 용도(Cyclohexenone oxime ethers, their preparation, and use thereof as herbicides) |